UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Phase 1, Open‐Label, Fixed‐Sequence, Drug–Drug Interaction Study of Zanubrutinib with Rifabutin in Healthy Volunteers

Clinical pharmacology in drug development, 2023-08, Vol.12 (8), p.832-838

2023

Volltextzugriff (PDF)

Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B‐Cell Malignancies

Clinical and translational science, 2021-03, Vol.14 (2), p.764-772

2021

Volltextzugriff (PDF)

Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator

CPT: pharmacometrics and systems pharmacology, 2021-05, Vol.10 (5), p.441-454

2021

Volltextzugriff (PDF)

In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor

Pharmacology research & perspectives, 2021-12, Vol.9 (6), p.e00870-n/a

2021

Volltextzugriff (PDF)

No QTc Prolongation With Zanubrutinib: Results of Concentration‐QTc Analysis From a Thorough QT Study in Healthy Subjects

Clinical and translational science, 2020-09, Vol.13 (5), p.923-931

2020

Volltextzugriff (PDF)

Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib

Expert review of clinical pharmacology, 2021-11, Vol.14 (11), p.1329-1344

2021

Volltextzugriff (PDF)

Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma

Leukemia & lymphoma, 2021-09, Vol.62 (11), p.2612-2624

2021

Volltextzugriff (PDF)

Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P‐gp and BCRP

British journal of clinical pharmacology, 2021-07, Vol.87 (7), p.2926-2936

2021

Volltextzugriff (PDF)

A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies

Leukemia & lymphoma, 2023-01, Vol.64 (2), p.329-338

2023

Volltextzugriff (PDF)

A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment

Leukemia & lymphoma, 2020-05, Vol.61 (6), p.1355-1363

2020

Volltextzugriff (PDF)

Investigations of methylmercury-induced alterations in neurogenesis

Environmental health perspectives, 2002-10, Vol.110 (suppl 5), p.859-864

2002

Volltextzugriff (PDF)

PB1926: EFFICACY AND SAFETY OF ONCE DAILY (QD) VS TWICE DAILY (BID) ZANUBRUTINIB FOR PATIENTS WITH VARIOUS B-CELL MALIGNANCIES: A COMPARATIVE SUMMARY OF CLINICAL DATA AND EXPOSURE-RESPONSE ANALYSES

HemaSphere, 2023-08, Vol.7 (S3), p.e70124b5

2023

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of CD4-Anchoring Bi-Functional Fusion Inhibitor in Monkeys

Pharmaceutical research, 2014-03, Vol.31 (3), p.809-818

2014

Volltextzugriff (PDF)

Integration of biostatistics and pharmacometrics computing platforms for efficient and reproducible PK/PD analysis: A case study

Journal of clinical pharmacology, 2013-11, Vol.53 (11), p.1112-1120

2013

Volltextzugriff (PDF)

Investigations of Methylmercury-Induced Alterations in Neurogenesis

Environmental health perspectives, 2002-10, Vol.110 (Suppl 5), p.859-864

2002

Volltextzugriff (PDF)

PB1926: EFFICACY AND SAFETY OF ONCE DAILY (QD) VS TWICE DAILY (BID) ZANUBRUTINIB FOR PATIENTS WITH VARIOUS B‐CELL MALIGNANCIES: A COMPARATIVE SUMMARY OF CLINICAL DATA AND EXPOSURE‐RESPONSE ANALYSES

HemaSphere, 2023-08, Vol.7, p.n/a

2023

Volltextzugriff (PDF)

Comparison of Proteasome Inhibition Activity between Carfilzomib and Bortezomib in the Phase 3 Endeavor Study

Blood, 2017-12, Vol.130, p.3125-3125

2017

Volltextzugriff (PDF)

p21(WAF1/CIP1) inhibits cell cycle progression but not G2/M-phase transition following methylmercury exposure

Toxicology and applied pharmacology, 2002-01, Vol.178 (2), p.117

2002

Volltextzugriff (PDF)

A physiologically based pharmacokinetic model for lactational transfer of PCB 153 with or without PCB 126 in mice

Archives of toxicology, 2007-02, Vol.81 (2), p.101-111

2007

Volltextzugriff (PDF)

A clonal growth model : Time-course simulations of liver foci growth following penta- or hexachlorobenzene treatment in a medium-term bioassay

Cancer research (Chicago, Ill.), 2001-03, Vol.61 (5), p.1879-1889

2001

Volltextzugriff (PDF)

Comparison of pharmacokinetic interactions and physiologically based pharmacokinetic modeling of PCB 153 and PCB 126 in nonpregnant mice, lactating mice, and suckling pups

Toxicological sciences, 2002, Vol.65 (1), p.26-34

2002

Volltextzugriff (PDF)

Induction of the Cell Cycle Regulatory Gene p21 (Waf1, Cip1) Following Methylmercury Exposure in Vitro and in Vivo

Toxicology and applied pharmacology, 1999-06, Vol.157 (3), p.203-212

1999

Volltextzugriff (PDF)

Induction of Growth Arrest and DNA Damage-Inducible Genes Gadd45 and Gadd153 in Primary Rodent Embryonic Cells Following Exposure to Methylmercury

Toxicology and applied pharmacology, 1997-11, Vol.147 (1), p.31-38

1997

Volltextzugriff (PDF)

Stochastic Simulation of Hepatic Preneoplastic Foci Development for Four Chlorobenzene Congeners in a Medium-Term Bioassay

Toxicological sciences, 2003-06, Vol.73 (2), p.301-314

2003

Volltextzugriff (PDF)

p21WAF1/CIP1 Inhibits Cell Cycle Progression but Not G2/M-Phase Transition Following Methylmercury Exposure

Toxicology and applied pharmacology, 2002-01, Vol.178 (2), p.117-125

2002

Volltextzugriff (PDF)

1 – 25 von 592

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(420)
Mit Volltextzugriff
(473)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A Phase 1, Open‐Label, Fixed‐Sequence, Drug–Drug Interaction Study of Zanubrutinib with Rifabutin in Healthy Volunteers

Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B‐Cell Malignancies

Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator

In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor

No QTc Prolongation With Zanubrutinib: Results of Concentration‐QTc Analysis From a Thorough QT Study in Healthy Subjects

Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib

Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma

Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P‐gp and BCRP

A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies

A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment

Investigations of methylmercury-induced alterations in neurogenesis

PB1926: EFFICACY AND SAFETY OF ONCE DAILY (QD) VS TWICE DAILY (BID) ZANUBRUTINIB FOR PATIENTS WITH VARIOUS B-CELL MALIGNANCIES: A COMPARATIVE SUMMARY OF CLINICAL DATA AND EXPOSURE-RESPONSE ANALYSES

Pharmacokinetics and Pharmacodynamics of CD4-Anchoring Bi-Functional Fusion Inhibitor in Monkeys

Integration of biostatistics and pharmacometrics computing platforms for efficient and reproducible PK/PD analysis: A case study

Investigations of Methylmercury-Induced Alterations in Neurogenesis

PB1926: EFFICACY AND SAFETY OF ONCE DAILY (QD) VS TWICE DAILY (BID) ZANUBRUTINIB FOR PATIENTS WITH VARIOUS B‐CELL MALIGNANCIES: A COMPARATIVE SUMMARY OF CLINICAL DATA AND EXPOSURE‐RESPONSE ANALYSES

Comparison of Proteasome Inhibition Activity between Carfilzomib and Bortezomib in the Phase 3 Endeavor Study

p21(WAF1/CIP1) inhibits cell cycle progression but not G2/M-phase transition following methylmercury exposure

A physiologically based pharmacokinetic model for lactational transfer of PCB 153 with or without PCB 126 in mice

A clonal growth model : Time-course simulations of liver foci growth following penta- or hexachlorobenzene treatment in a medium-term bioassay

Comparison of pharmacokinetic interactions and physiologically based pharmacokinetic modeling of PCB 153 and PCB 126 in nonpregnant mice, lactating mice, and suckling pups

Induction of the Cell Cycle Regulatory Gene p21 (Waf1, Cip1) Following Methylmercury Exposure in Vitro and in Vivo

Induction of Growth Arrest and DNA Damage-Inducible Genes Gadd45 and Gadd153 in Primary Rodent Embryonic Cells Following Exposure to Methylmercury

Stochastic Simulation of Hepatic Preneoplastic Foci Development for Four Chlorobenzene Congeners in a Medium-Term Bioassay

p21WAF1/CIP1 Inhibits Cell Cycle Progression but Not G2/M-Phase Transition Following Methylmercury Exposure

Suchergebnisse filtern